Cargando…
The Novel Oncolytic Compound LTX-401 Induces Antitumor Immune Responses in Experimental Hepatocellular Carcinoma
LTX-401 is a novel oncolytic compound designed for the local treatment of solid tumors. In the present study, we have examined the applicability and efficacy of LTX-401 in a rat model JM1 hepatocellular carcinoma, with particular interest in its ability to induce antitumor immunity. LTX-401 induces...
Autores principales: | Mauseth, Brynjar, Camilio, Ketil André, Shi, Jihua, Hammarström, Clara Louise, Rekdal, Øystein, Sveinbjørnsson, Baldur, Line, Pål-Dag |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562107/ https://www.ncbi.nlm.nih.gov/pubmed/31211244 http://dx.doi.org/10.1016/j.omto.2019.05.002 |
Ejemplares similares
-
The Cytolytic Amphipathic β(2,2)-Amino Acid LTX-401 Induces DAMP Release in Melanoma Cells and Causes Complete Regression of B16 Melanoma
por: Eike, Liv-Marie, et al.
Publicado: (2016) -
Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model
por: Camilio, Ketil A., et al.
Publicado: (2019) -
LTX-315 (Oncopore™): A short synthetic anticancer peptide and novel immunotherapeutic agent
por: Camilio, Ketil André, et al.
Publicado: (2014) -
Complete regression and systemic protective immune responses obtained in B16 melanomas after treatment with LTX-315
por: Camilio, Ketil André, et al.
Publicado: (2014) -
Oncolytic peptide LTX-315 induces an immune-mediated abscopal effect in a rat sarcoma model
por: Nestvold, Janne, et al.
Publicado: (2017)